Note 8 - Subsequent Events

3 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Subsequent Events [Text Block]

( 8 ) Subsequent Events

On

October 30, 2017,

the Company announced that it had entered into

the Merger Agreement pursuant to which Vaxart., a privately-held clinical-stage company focused on developing oral recombinant vaccines from its proprietary delivery platform, would become a wholly-owned subsidiary of the Company. This transaction marks the culmination of the Company’s Strategic Review process which was initiated in

April.

The Merger will result in a combined company focused on developing orally-delivered vaccines and therapeutics to address a variety of viral infections.